HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A massive shift in the shareholding pattern of pharmaceutical player Corona Remedies Limited took place on June 17, 2026, as major institutional players executed a significant block deal. The transaction saw marquee names like HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA) stepping in to absorb a massive stake offloaded by private investors.
The Mechanics of the ₹777 Crore Divestment
The block deal was primarily driven by Sepia Investments, which offloaded 43,28,943 shares of Corona Remedies. At a transaction price of ₹1,730 per share, Sepia’s stake amounted to approximately ₹748.9 crore. Adding to this divestment, a second seller, Anchor Partners, sold 1,61,861 shares at the same price, contributing an additional ₹28 crore to the deal.
In total, the two sellers successfully exited or reduced their positions by worth approximately ₹776.9 crore. The execution of such a large-scale transaction at a uniform price of ₹1,730 per share highlights the strong institutional appetite for the pharmaceutical company’s stock despite the large volume.
HDFC Mutual Fund Emerges as the Dominant Buyer
The buy side of the deal was equally impressive, featuring twelve distinct institutional investors. HDFC Mutual Fund emerged as the primary driver of the transaction, acquiring 24,50,000 shares. This purchase, valued at roughly ₹423.9 crore, accounted for more than half of the total deal value, signaling high confidence from India's leading asset manager.
Other significant domestic and international players included:
- Aditya Birla Sun Life Mutual Fund: Purchased 4,90,000 shares worth ₹84.8 crore.
- Invesco Mutual Fund: Acquired 2,89,017 shares valued at ₹50 crore.
- Kotak Mahindra Mutual Fund: Picked up 1,61,861 shares worth ₹28 crore, exactly matching the quantity sold by Anchor Partners.
- WhiteOak Capital Mutual Fund: Bought 1,45,000 shares for ₹25.1 crore.
Global Institutional Interest in Corona Remedies
The deal also showcased significant interest from international sovereign and asset management funds. The Abu Dhabi Investment Authority (ADIA) participated by purchasing 39,130 shares worth ₹6.8 crore.
غولهای بینالمللی نیز حضور خود را نشان دادند:
- نهادهای Aberdeen Asset Management: Aberdeen Asian Smaller Companies Investment Trust Plc تعداد ۴۵۰,۸۶۸ سهم (۷۸ کرور روپیه) خرید، در حالی که صندوق Aberdeen Standard Sicav I تعداد ۲۷۴,۱۳۲ سهم (۴۷.۴ کرور روپیه) خریداری کرد.
- صندوقهای WhiteOak و Ashoka: صندوق India Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fund مبلغ ۲۵.۷ کرور روپیه سرمایهگذاری کرد، در حالی که صندوق Ashoka WhiteOak ex China مبلغ ۵.۱ کرور روپیه به سمت خرید اضافه کرد.
مشارکتهای کوچکتر اما قابل توجه از سوی Factory Mutual Insurance Company (۱.۹ کرور روپیه) و TCW White Oak Emerging Markets Equity Fund (۳۳ لک روپیه) انجام شد که مجموعهای متنوع از سرمایههای جهانی وارد شرکت را تکمیل میکند.
نکات کلیدی
- خروج بزرگ: Sepia Investments و Anchor Partners در مجموع حدود ۷۷۶.۹ کرور روپیه از سهام Corona Remedies را از طریق یک معامله بلوکی واگذار کردند.
- تسلط HDFC MF: صندوق HDFC Mutual Fund بزرگترین خریدار بود که بیش از ۴۲۳ کرور روپیه از سهام را جذب کرد که بیش از ۵۰ درصد از کل حجم معامله را شامل میشود.
- پروفایل متنوع خریداران: این معامله ترکیبی از غولهای داخلی (Aditya Birla، Kotak، Invesco) و نهادهای بینالمللی (ADIA، Aberdeen، WhiteOak) بود که نشاندهنده علاقه گسترده نهادهای سرمایهگذاری است.